Updated:
Discovery Life Sciences
Discovery Life Sciences launched in 2007 as a specialized immunohistochemistry lab in Huntsville, Alabama.
Discovery Life Sciences
Discovery Life Sciences launched in 2007 as a specialized immunohistochemistry lab in Huntsville, Alabama. CEO Glenn Bilawsky joined in 2016 and fundamentally repositioned the company, pivoting from a regional service provider to a national consolidator of biospecimen repositories, genomic datasets, and analytical laboratories. The firm now operates as a contract research backbone, supplying human tissue, blood, and cellular materials alongside multi-omics data generation capabilities to pharmaceutical and biotechnology clients. The company spans three integrated divisions: Biospecimens, Biomarker Services, and Cell & Gene Therapy Solutions. Its procurement network sources disease-state and normal human tissue across oncology, immunology, neurology, and cardiometabolic disease areas. Biomarker Services runs genomic, proteomic, and spatial biology assays from facilities in the US and Europe. Cell & Gene Therapy capabilities include cell isolation, assay development, and flow cytometry for translational research and clinical trials. Major pharmaceutical firms use Discovery's platform for patient stratification and companion diagnostics development. Bilawsky engineered a rapid acquisition campaign starting in 2018, folding in competitors and adjacent services including Conversant Bio, the HudsonAlpha Institute's clinical sequencing lab, and QualTek Molecular Laboratories. By 2022 the company employed roughly 800 people across multiple campuses in Huntsville and satellite operations reportedly reaching into Pennsylvania and Europe. Its repository held approximately 2 million human biospecimens at that time, with embedded clinical-outcome data from consented donors (per public record). The company is owned by private equity firm Astorg since its 2022 acquisition from prior backers. Discovery Life Sciences represents a structural outlier in the life-sciences supply chain: it owns both the raw research material — the specimens and the consent infrastructure — and the downstream analytical services that generate the data. That vertical integration gives it pricing power and switching costs that disaggregated contract research organizations cannot easily replicate, while its Alabama headquarters keeps operational overhead below coastal peer benchmarks.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Huntsville
Corporate office
Huntsville, AL, United States
Principals
Glenn Bilawsky
CEO
Sector focus
Frequently asked questions
Who runs Discovery Life Sciences and how is it structured?
Glenn Bilawsky has served as CEO since 2016, having repositioned the company from a focused lab into a multi-division biospecimen and analytics platform. The company was acquired by private equity firm Astorg in 2022 from prior investors. It operates as a for-profit contract research organization, not a single-family office or university-affiliated institute, serving pharmaceutical sponsors through integrated laboratory and logistics divisions.
What kind of biospecimens does Discovery Life Sciences provide?
The company's repository, pegged at approximately 2 million human biospecimens as of 2022 (per public record), covers solid tumor tissue, blood components, bone marrow, and non-oncology disease-state materials including cardiovascular and neurological indications. Specimens are sourced through a consented donor network and clinical site partnerships, with linked de-identified patient outcomes used for biomarker validation and companion diagnostic programs.
Does Discovery perform only procurement, or does it also generate laboratory data?
Discovery integrates both. Its Biomarker Services division generates multi-omics data — including next-generation sequencing, spatial transcriptomics, multiplex immunohistochemistry, and proteomics — from its biobanked and client-provided specimens. This dual model separates the firm from pure-specimen brokers, enabling a single-provider workflow from tissue acquisition through assay-ready datasets.
What role does Discovery play in cell and gene therapy research?
The firm's Cell & Gene Therapy Solutions unit supplies leukopaks, whole blood, and isolated cell products including CD3+ and CD34+ selections. It runs flow cytometry, potency assays, and process-development support for autologous and allogeneic therapy programs, typically engaging at the preclinical through early clinical stage.
How is Discovery Life Sciences valued or funded?
Financial terms of the 2022 Astorg acquisition were not publicly disclosed, and the company does not publish revenue or deployment figures. As a privately held, sponsor-backed entity, it is valued on its laboratory capacity, specimen inventory scale, and contractual pharma partnerships rather than a publicly reported asset base.
Does Discovery serve academic researchers or only commercial pharma clients?
While the firm's primary client base includes 8 of the top 10 global pharmaceutical companies, its procurement network and laboratory services are also available to academic medical centers, government research programs, and clinical cooperative groups through standard master services agreements.
What role did acquisitions play in shaping Discovery's current footprint?
The company executed over a dozen acquisitions from 2018 onward, absorbing firms including Conversant Bio, the HudsonAlpha Institute for Biotechnology's clinical sequencing laboratory, and QualTek Molecular Laboratories. This inorganic expansion built its dual physical presence in Huntsville and Pennsylvania, added European lab capacity, and consolidated a fragmented biospecimen broker market under one operational umbrella.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: